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Genomic integrity is constantly threatened by sources of DNA damage, internal and external alike. Among the most cytotoxic
lesions is the DNA double-strand break (DSB) which arises from the cleavage of both strands of the double helix. Cells boast
a considerable set of defences to both prevent and repair these breaks and drugs which derail these processes represent an
important category of anticancer therapeutics. And yet, bizarrely, cells deploy this verymachinery for the intentional and calculated
disruption of genomic integrity, harnessing potentially destructiveDSBs in delicate genetic transactions.Under tight spatiotemporal
regulation, DSBs serve as a tool for genetic modification, widely used across cellular biology to generate diverse functionalities,
ranging from the fundamental upkeep of DNA replication, transcription, and the chromatin landscape to the diversification of
immunity and the germline. Growing evidence points to a role of aberrant DSB physiology in human disease and an understanding
of these processes may both inform the design of new therapeutic strategies and reduce off-target effects of existing drugs. Here,
we review the wide-ranging roles of physiological DSBs and the emerging network of their multilateral regulation to consider how
the cell is able to harness DNA breaks as a critical biochemical tool.
1. Introduction
Just as DNA breakage can devastate genomic integrity, it can
also be deliberately and precisely exploited by cells in feats
of genetic craftsmanship. Indeed, various integral cellular
processes and genetic transactions are underpinned by the
measured use of such potentially deleterious breaks.
The genome is continuously exposed to a panoply of
DNA damaging agents, both endogenous and exogenous,
which pose a considerable threat to genomic integrity. These
genotoxic insults result in diverse DNA lesions including
mismatches, base adducts, pyrimidine dimers, intra- and
interstrand cross links, DNA-protein adducts, and strand
breaks [1]. Among themost noxious lesions are DNA double-
strand breaks (DSBs)wherein both strands of the double helix
are broken through cleavage of phosphodiester linkages in the
backbone of the duplex [2]. There is great variation among
DSBs both structurally and in terms of the mechanisms of
their generation. While simple DSBs such as those gener-
ated by restriction endonucleases may have either blunt or
staggered ends, DSBs induced by physical or chemical agents,
such as by ionising radiation and radiomimetic chemicals,
both of which are used in cancer therapy, can display
increased complexity. This includes chemical modifications
of termini, differing latency of generation, indirect DSB
formation from processing of other forms of DNA dam-
age, and chromatin destabilisation from clustering of DSBs
[3].
DSBs are highly mutagenic and can induce potentially
tumorigenic chromosomal translocations. If unrepaired,
DSBs may also lead to cell death [4]. It is thus of utmost
primacy that such cytotoxic breaks are rapidly detected,
signalled, and repaired. Indeed, DSBs elicit a potent DNA
damage response (DDR) comprising DNA repair, cell cycle
arrest, and/or apoptosis [2]. Two major pathways operate in
eukaryotic cells in the repair of endogenously or exogenously
induced DSBs: nonhomologous end-joining (NHEJ) and
homologous recombination (HR). Unlike error-prone NHEJ
which operates throughout the cell cycle, HR is essentially
error-free and is limited to the S and G2 phases [5].
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Despite the dangers inherent in such lesions, DSBs are
precisely employed for the intentional but controlled disrup-
tion of genomic integrity in biological processes. The cellular
roles of physiological DSBs can be broadly considered as
one of two major functionalities: genetic recombination or
manipulation of DNA topology. In the former role, DSBs
can act as genomic “shufflers,” carefully but permanently
recombining DNA segments for genomic diversification
in lymphocytes [6, 7] and germ cells [8]. In contrast,
topoisomerase-mediated DSBs serve as genomic “sculptors,”
modulating higher-order DNA structure and serving to
facilitate DNA replication and transcription [9–11], regulate
gene expression [12–15], and alter chromatin state [16, 17].
While this latter form of DSB may, at first glance, appear to
be little more than a transient intermediate, these “cleavage
complexes” are structurally DSBs, also exist as longer-lived
species, can be endogenously or exogenously converted into
abortive breaks, and are highly spatiotemporally regulated
to both produce functionally diverse genomic contortions
and prevent genotoxicity or failure of genetic transactions
[18, 19]. Hence, both sources of DSB will be considered in this
discussion.
Here, we review the wide-ranging biological functions of
these various physiologicalDSBs and themultilayered regula-
tion thereof, together constituting cellular “DSB physiology”
(Figure 1). By considering DSB physiology in its various
forms, we explore how the cell is able to harness potentially
destructive DSBs in delicate genetic operations.
2. Genetic Recombination: DSBs as
Genomic Shufflers
2.1. Physiological DSBs in V(D)J Recombination. The role
of physiological DSBs in the diversification of the adaptive
immune response is well documented. V(D)J recombination
describes the process whereby lymphoid cells recombine a
repertoire of germline variable (V), diversity (D), and joining
(J) exon gene segments in various permutations to generate
enormous antigen-receptor diversity in immunoglobulins
(Ig) and T cell receptors (TCRs). All three exon segments are
used for assembling the variable region of the Ig heavy chain
and the TCR 𝛽 and 𝛿 chains, whereas only V and J segments
are required for the Ig light chain and TCR 𝛼 and 𝛾 chains
[20].The process involves large genomic rearrangements and
DSBs act in these processes as “recombinogenic biomarkers,”
specifying the recruitment of the recombinatorial machinery.
It thus follows that the spatiotemporal regulation of DSB
induction and repair is critical to the precise execution of
this genetic shuffling, and perturbations thereof can produce
disease in humans. The mechanism proceeds as two broad
phases, cleavage and joining, corresponding to the processes
of DSB formation and DSB resolution, respectively.
2.1.1. Cleavage: DSB Formation. Each V, D, and J segment is
flanked by a recombination signal sequence (RSS), compris-
ing conserved heptamer-spacer-nonamer sequence elements
[21, 22]. Cleavage is initiated by the recognition of these RSS
elements by the lymphoid-cell specific recombinase complex
[23, 24]. Components of this complex, RAG-1 and RAG-2,
bind one RSS from each of the paired gene segments, to form
RAG-RSS complexes associated with each signal sequence
[25, 26]. The two RSS groups are then approximated and
synapsis proceeds to form a precleavage synaptic complex
(PcSC).ThePcSC is typically directed between gene segments
with different RSS spacer lengths (either 12 or 23 base pairs)
conforming to the 12/23 restriction rule [27]. PcSC forma-
tion is facilitated by the DNA-bending high-mobility group
proteins HMGB1 and HMGB2 which are widely involved in
chromatin architecture [28]. Here, HMGB1/2 act to enhance
RAG1/2 binding to and cleavage of the 23 RSS, possibly via
stabilisation of RAG-mediated bending of the 23 RSS spacer
[29–33].The RAG proteins proceed to introduce a nick at the
junction between the RSS heptamer and coding sequence.
While RAG-1 alone but not RAG-2 possesses DNA-binding
activity and can mediate signal recognition, association of
RAG-1withRAG-2 increases sequence specificity and the sta-
bility of the enzyme-DNA complex [34, 35]. Nick formation
is followed by a RAG1-mediated transesterification reaction
forming a DSB comprising a blunt 5󸀠-phosphorylated signal
end and a hairpin coding end [23, 36]. The DSB is then
enclosed in a postcleavage synaptic complex before NHEJ
repair in the joining phase [37].
2.1.2. Joining: DSB Resolution. Prior to joining, hairpin cod-
ing ends are nicked open through the endonuclease activity
of the nuclear enzyme Artemis, which complexes with the
serine/threonine kinase DNA-PKcs, which, in turn, activates
Artemis by phosphorylation [38, 39]. However, studies also
indicate a postcleavage role for RAG proteins in opening
hairpin coding ends through 3󸀠-flap endonuclease activity
[40–42] as well as serving as a scaffold to shield theDNA ends
from aberrant nuclease digestion [43]. Modifications during
recombination are introduced through Artemis-mediated
asymmetric hairpin opening and/or terminal deoxynu-
cleotidyl transferase- (TdT-) mediated nucleotide addition.
The former mechanism enables palindromic repeat or “P”
nucleotide addition as well as nucleotide loss from coding
ends [44], while TdT-mediated addition inserts random “N”
nucleotides at coding ends in a 5󸀠-to-3󸀠 direction [38, 45].
TdT, a template-independent polymerase, is recruited by a
complex of NHEJ repair proteins comprising XRCC4, DNA
ligase IV, and DNA-PK (itself a complex of Ku70, Ku86,
and DNA-PKcs) [46–49]. The subsequent activity of DNA
polymerase 𝜆 and 𝜇 combined with exonucleases generates
compatible coding ends [50, 51] which are then ligated by
the XRCC4-DNA ligase IV-XLF complex to produce the
recombined V(D)J product [46, 47, 52].
2.1.3. Regulation of DSBs in V(D)J Recombination. An impor-
tant point of control in the DSB formation step of V(D)J
recombination is the cell cycle-dependent regulation of
RAG expression. Cyclin A-CDK2 phosphorylation-mediated
degradation of RAG-2 at the G1/S transition [53] exerts tem-
poral control over RAG-induced DSBs by restricting RAG2
expression to the G1 phase of the cell cycle [54]. Further-
more, in p53-deficient mice a nonphosphorylatable T490A
mutation of the phosphodegron in the C-terminus of RAG-
2 results in increased lymphoma formation characterised by
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Figure 1: Summary of the diverse roles of physiological DSBs in biological processes.
an increased frequency of clonal chromosomal translocations
[55], illustrating the importance of this regulation for the
integrity of recombination.
Additional temporal control is exerted over RSS selection
for DSB formation and only certain RSS sites are available
for recombination, exhibiting cell- and stage-specific biases
[56, 57]. The great accuracy of the recombinatorial machin-
ery, both in RSS specification and in avoiding inauthentic
RSS-like (cryptic RSS; cRSS) sites, which occur around once
per 600 bases in random DNA sequences [58], involves
controlling the accessibility of the recombinase to its substrate
for DSB generation. The discovery of the concurrence of IgH
variable region (VH) germline transcription with its joining
with DJH suggested an open chromatin state was required
for recombination [57]. This “accessibility hypothesis” is now
thought to involve chromatin architectural changes brought
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about by DNA and epigenetic modifications, chromatin-
binding proteins, and cis-acting enhancer elements. These
ultimately produce a transcriptionally active locus charac-
terised by DNA hypomethylation, activating histone mod-
ifications, DNase I sensitivity, and increased RNA poly-
merase II occupancy [59–64]. RAG2 has been shown to
specifically recognise the histone modification H3K4me3, a
marker enriched at active promoters, via its PHD finger, an
interaction which also stimulates RAG complex activity [65,
66].This recognition likely serves to localise the recombinase
to target RSSs by active promoters and upregulate recombi-
nation thereat [64]. Modulation of chromatin packing also
determines the order of rearrangement observed in B cell Ig
(heavy chain before light chain) and T cell TCR (𝛽 chain
before 𝛼 chain), as well as the process of allelic exclusion [56].
Aside frommodulation of accessibility of RSS sites to binding
and cleavage by the recombination machinery, target locus
position within chromatin compartments of the nucleus and
the structure of the locus itself are also directed to facilitate
recombination [64].
2.1.4. Dysregulation of DSB Physiology in V(D)J Recombi-
nation. Broadly, perturbations in V(D)J recombination can
be from either an inability to form DSBs, an inability to
repair them, or inaccurate pairing of RSSs. Although viable,
Rag-1- or Rag-2-deficient mice are unable to carry out
V(D)J recombination and lack mature B and T lymphocytes,
presenting with severe combined immune deficiency (SCID)
[67, 68]. Missense mutations in either RAG-1 or RAG-2 genes
are also observed in humans with an analogous form of
autosomal recessive SCID known as Omenn syndrome [69].
Genetic studies of polymorphisms in wild-type and Omenn
syndrome patients as well as biochemical data characterising
recombinatorial competence of Omenn syndrome mutants
suggest that RAG-1 and RAG-2 mutants exhibit lower effi-
ciency of V(D)J recombination [69]. These mutations are
associated with decreased RAG DNA-binding and cleavage
activity and a lower efficiency of interaction between RAG
proteins [69].
Impairment of the joining phase of V(D)J recombination
can also cause immunodeficiency. While all mammalian
NHEJ pathway mutants display sensitivity to ionising radi-
ation and a lack of B and T lymphocytes, a spectrum of
phenotypes is observed in mouse models. DNA-PKcs and
Artemis mutants exhibit subtle defects in DSB repair [70]
but display no growth retardation [71]. Hairpin opening is
lost in Artemis-deficient SCID [72] andDCLRE1C hypomor-
phism in humans has been found to underlie an Omenn
syndrome phenotype associated with defective endonucle-
ase activity [73]. Ku70 and Ku80 mutants display similar
phenotypes of radiosensitivity and growth retardation [74,
75] likely due to the interdependence conferred by their
heterodimerisation [76]. Mutants of the critical end-joining
proteins XRCC4 and DNA ligase IV have the most severe
phenotype, both displaying V(D)J recombination defects,
impaired lymphocyte development, p53-dependent neuronal
apoptosis, and embryonic lethality [77–79]. These findings
thus point towards a crucial role of DSB repair in B/T cell
physiology and adaptive immune diversification.
Lymphomas have been found to exhibit a range of chro-
mosomal aberrations as a result of erroneous DSB handling
in V(D)J recombination. Oncogenic lesions have been found
to include chromosomal translocations, insertions, deletions,
and inversions and broadly result from errors in RSS pairing
or joining [80–82]. Inaccurate RSS recognition can produce
RSS/cRSS pairings which may exert tumorigenic effects via
amplification of a protooncogene or juxtaposition of tran-
scriptional regulatory elements from the antigen-receptor
locus with a protooncogene, driving dysregulated expression
[6]. cRSS/cRSS pairings may also arise which can produce
translocations or deletions [6]. Aberrant DSB formation
has also been found to underlie the reciprocal (t14; 18)
translocation found in 90% of follicular lymphomas [83, 84].
In this case, it has been shown that cleavage of non-B-form
DNA at a non-RSS “translocation fragile zone” called the
major breakpoint region (MBR) at the Bcl-2 gene produces
a translocation with the DSB at the Ig heavy chain locus
on chromosome 14 [84]. Recent work on minichromosomal
substrates has revealed the importance of CpGmethylation in
the localisation of aberrant DSB formation at the Bcl-2 MBR
and that breakage is AID-dependent (activation-induced
cytidine deaminase) [85]. Lymphomas have also been found
to exhibit defects in DSB joining producing chromosome
translocations by the “end donation”model.This involves the
erroneous joining of a RAG-inducedDSB at an authentic RSS
with a non-RAG-mediated DSB [86].
2.2. Physiological DSBs in Class Switch Recombination. Class
switch recombination (CSR) is another example of a DSB-
dependent recombination event, occurring in mature B cells.
In response to antigenic stimuli and costimulatory signals
from other immune cells, B cells undergo CSR to alter their
Ig constant heavy chain while retaining the same antigen
specificity, in effect, generating an alternative Ig isotype
with the same paratope but distinct effector functions [87].
This enables a permanent switch of expression from the
default IgM and IgD to alternative Ig isotypes (IgA, IgG,
or IgE) by recombination of the heavy chain (IgH) locus.
Recombination is achieved through cleavage and excision
of constant heavy chain (CH) genes via DSB generation,
followed by ligation of the remaining segments through DSB
resolution [87].
Conserved motifs called switch (S) regions upstream
of each CH gene are the site of DSB generation [88, 89].
AID initiates recombination by conversion of multiple S
region deoxycytidine residues into deoxyuracil [90–93].
The resulting UG mismatch can be converted into a DSB
through base-excision repair (BER) and/or mismatch repair
(MMR) DNA repair pathways [87]. BER proceeds through
excision of deoxyuracil by uracil DNA glycosylase (UNG)
[93, 94] followed by nicking of the resulting abasic site by
apurinic/apyrimidinic endonucleases (APE) [87, 95]. AID-
mediated deamination on the opposite strand introduces a
secondnick in close proximity, thereby generating a staggered
DSB [89, 96]. Processing of these overhangs forms blunt free
DNA ends which are permissive for shuffling [87, 97].
As aforementioned, MMR is another pathway employed
in CSR DSB generation and is thought to provide auxiliary
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support to BER-mediated mismatch excision [98]. Indeed,
multiple studies ofMMR-deficientmurine B cells have shown
impaired and aberrant CSR implicatingMMRproteinsMsh2,
Msh6, Mlh1, Pms2, and Exo1 in the recombination process
[99–104]. Onemodel proposes that while the aforementioned
BER-induced SSBs can automatically form DSBs if near one
another, distant SSBs within the large S regions can be
converted into DSBs by assistance from MMR [105]. This
first involves recognition of an AID-induced UG mismatch
by a heterodimer of Msh2-Msh6, followed by recruitment
of the endonuclease heterodimerMlh1-Pms2.These proteins,
in turn, recruit the 5󸀠-3󸀠 exonuclease Exo1 to a nearby BER-
induced 5󸀠 SSB and Exo1 proceeds to excise the strand
towards the mismatch and beyond until it reaches another
SSB, thus producing aDSB [105]. Alternatively it has also been
proposed that if Exo1-generated single-stranded DNA gaps
are formed on opposite strands, this too may form a DSB
[106].
After intrachromosomal deletion of the intervening
unwanted CH genes, the free end of the variable domain
region is ligated to that of the new constant domain exon by
the NHEJ machinery [107–110].
2.2.1. Regulation of DSBs in CSR. Recombination underlying
isotype switching of constant heavy chain genes is regulated
by germline transcripts which modify switch region accessi-
bility to the DNA handling machinery [105]. Transcription
beginning at germline promoters, upstream of a target S
region, generates a sterile (noncoding) transcript known as
a germline transcript (GT) [111, 112]. Activation of specific
cytokine-inducible transcription factors and their action at
germline promoters determines which GT is generated [113].
These germline transcripts direct AID to specific S regions
thus spatially regulating DSB generation and, in turn, CSR
[105, 114].
AID deamination can only occur on single-stranded
DNA (ssDNA) [115] and one proposed mechanism of GT-
mediated regulation is optimisation of S region structure for
AID recognition [115]. This could be achieved through the
creation of short ssDNA tracts in the S regions, paralleling
somatic hypermutation [116], or through RNA-DNA hybrid
R-loop formation [117, 118]. AID can also be directly recruited
to RNA Pol II at the initiation or elongation phase of GT
formation, which may facilitate AID targeting [105, 119].
Further regulation may also occur at the level of higher-
order chromatin structure whereby histone modifications in
the transcribed region may modulate AID accessibility [120].
While the exact mechanism of this architectural control is
unclear, it appears to be associated with B cell activation, AID
expression, and RNA Pol II enrichment [120, 121]. It is thus
clear that various levels of regulation act to spatiotemporally
restrain DSB formation and repair in CSR.
2.3. Physiological DSBs in Meiotic Recombination. Beyond its
roles in lymphoid cells, DSB-induced recombination also acts
inmeiosis where it is essential for both the fidelity of chromo-
some segregation and diversification of the germline. Meiosis
is a form of reductive cell division exclusive to gametogenesis
and involves two successive divisions following replication,
known as MI andMII [122]. A hallmark of meiosis is meiotic
recombination between homologous chromosome pairs or
dyads, which is reliant on DSB induction and HR repair,
resulting in exchange of genetic information between non-
sister chromatids [122]. These “crossover” events essentially
produce shuffling of alleles in each chromatid, giving rise
to a unique haploid complement in the resultant gametes,
ultimately creating genetic diversity within the population.
Furthermore, meiotic recombination establishes physical
linkages between homologs allowing accurate segregation by
the spindle apparatus [123]. Just as in V(D)J recombination
and CSR, careful spatiotemporal regulation of DNA break
induction and resolution is critical to the integrity of the
process.
2.3.1. DSB Formation. Meiotic recombination is initiated
by DSB induction by a dimer of the topoisomerase-like
transesterase Spo11 which acts via a covalently linked protein
tyrosyl-DNA intermediate complex [124–127]. Interestingly,
the human SPO11 homolog maps to position 20q13.2-q13.3,
a region known to be amplified in some breast and ovarian
tumours, possibly reflecting genomic instability due to dys-
regulation of DSB formation [128]. Spo11 action is critical
for gametogenesis and loss in mice produces infertility and
results in defective meiotic recombination, DSB formation,
and synapsis in Spo11−/− mouse spermatocytes [129]. DSB
formation is also dependent on an extensive protein-protein
interaction network, most studied in S. cerevisiae, between
Spo11 and other meiotic proteins. These proteins include
components of the Mre11-Rad50-Xrs2 (MRX) complex and
multiple Spo11-accessory proteins including Mei4, Mer2,
Rec102, Rec104, Rec114, and Ski8 which facilitate DSB for-
mation [126, 130]. The functions of these various proteins
are incompletely understood; however, the WD repeat pro-
tein Ski8 has been found to stabilise association of Spo11
on meiotic chromatin and promotes recruitment of other
accessory proteins [130] and Rec102 and Rec104 are known to
form a multiprotein complex with Spo11 and act with Rec114
to regulate Spo11 self-association [131–133]. Rec 114, Mer2,
and Mei4 (RMM) constitute a separate subcomplex [134]
which plays a role in the spatiotemporal regulation of DSB
formation as will be discussed below.
2.3.2. DSB Resolution. The resulting DSBs then undergo
endonucleolytic processing which releases Spo11 to allow
repair [135]. This initial DSB resection is coordinated with
cell cycle progression and is dependent on the activity of
the multisubunit nuclease MRX complex and Sae2 pro-
tein in budding yeast [126, 136–138]. The former complex
also acts to facilitate HR independently of its nucleolytic
activity [139]. Analogous to the MRX complex, the MRE11-
RAD50-NBS1 (MRN) complex possesses a similar role in
SPO11 removal in other eukaryotes [140]. Spo11 removal is
followed by extension of the end resection, involving the
helicase Sgs1 and nucleases Exo1 and Dna2, forming 3󸀠
single-stranded overhangs for HR [138, 141]. The overhangs
then undergo homology search and strand invasion catal-
ysed by the strand exchange proteins Rad51 and meiosis-
specific Dmc1 alongside various other cofactors [142, 143].
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The resulting interactions are processed to form recombi-
nation products with either noncrossovers or crossovers,
defined, respectively, as gene conversion or reciprocal genetic
exchange between homologous chromosomes [142]. During
this pairing or synapsis of dyads, a proteinaceous structure
called the synaptonemal complex establishes a zipper-like
connection between homologous chromosomes [144]. Recip-
rocal interhomolog recombination results in the formation of
physical linkages between homologous chromosomes known
as chiasmata, which aid coalignment of the resultant bivalents
along the spindle axis for accurate segregation [145].
2.4. Regulation of DSBs in Meiotic Recombination. A multi-
tude of interacting mechanisms operate in meiotic recombi-
nation to control DSB formation and resolution. This tight
spatiotemporal regulation of DSB handling allows the inten-
tional disruption of gamete DNA integrity for diversification,
while ensuring coordinated cell cycling and, ultimately, gen-
eration of an intact haploid germline.
2.4.1. Temporal Control of Meiotic DSBs. DSB induction is
mechanistically coupled to DNA replication [146] and is sub-
ject to strict temporal regulation [147–149], occurring only
between replication and chromosome segregation [150]. This
ensures both coordinated chiasma formation and effective
homology search for synapsis [150]. In addition, a multi-
tude of checkpoints operate to couple DSB induction and
resolution to the cell cycle to protect against the deleterious
effects of unrepaired DSBs and also act to arrest or eliminate
aberrant cells [151–154].
Posttranslational modifications on the Spo11-accessory
protein Mer2 have been shown to contribute to the timely
execution of DSB formation in meiotic recombination. Phos-
phorylation of Mer2 by the budding yeast cyclin-dependent
kinase Cdc28 stimulates DSB formation via promotion of
interactions both with itself and with other proteins involved
in DSB generation including Mei4, Rec114, and Xrs2 [155].
It is known that Cdc28-Clb5 (CDK-S) activity increases
during premeiotic replication and peaks before MI [156, 157]
and thus may help orchestrate a concerted progression of
meiotic recombination and prophase I [155]. Mer2 is also
phosphorylated by Cdc7 kinase in S. cerevisiae to control
Spo11 loading on DSB target sites [158]. It has been found
that CDK-S phosphorylation on Mer2 S30 promotes DDK
(Cdc7-Dbf4)-dependent phosphorylation at the adjacent S29
[157]. As well as being involved in meiotic recombination,
CDK-S and DDK are both required for premeiotic S phase
[156, 159] which may contribute to coordination therewith.
Furthermore, it has been found that the level of DDK activity
required for premeiotic S phase is lower than that supporting
its postreplicative role in meiosis [159]. It has been proposed
that different thresholds for both CDK-S and DDK in these
processes may ensure replication precedes DSB formation
[160].
Additional temporal control is afforded by meiosis-
specific expression of Spo11 and accessory proteins Rec102,
Rec104, Rec114, andMei4, largely achieved via transcriptional
regulation [150]. In contrast,Mer2 has been found to undergo
meiosis-specific posttranscriptional regulation by a splicing
factor Mer1, which itself is only expressed in meiosis [161,
162]. Although Mer2 transcription does occur in mitosis,
efficient splicing by Mer1 to generate functional Mer2 is
exclusive to meiosis [161].
2.4.2. Spatial Control of Meiotic DSBs. Meiotic recombi-
nation and DSB formation exhibit nonrandom patterning
across the genome, being more frequently localised to par-
ticular sites on chromosomes called “hotspots” [163, 164].
While exchange usually takes place between alleles, homolo-
gous recombination between nonallelic sequences with high
sequence identity may occur when DSBs form in repetitive
DNA sequences such as transposable elements and low-
copy repeats/segmental duplications, leading to genomic
rearrangements [165]. In addition, it has been shown that
DSBs formed in pericentromeric regions are associated with
disruption of sister chromatid cohesion leading to misseg-
regation and aneuploidy [166]. Therefore, the location of
DSBs and subsequent recombination is controlled for the
maintenance of genomic integrity.
In mice, recombination hotspots have been found to
be enriched for H3K4me3 histone modifications [167, 168].
These hotspots are determined by the DNA-binding histone
H3K4 trimethyltransferase PRDM9, which has been found
to regulate activation of recombination loci and is a key
factor in specification of meiotic DSB distribution [169, 170].
Indeed, Prdm9-deficiency results in infertility and disruption
of early meiotic progression in mouse models [171]. PRDM9
has been shown to directly and specifically bind a 13-mer
DNAmotif enriched at hotspots via its C2H2-type zinc finger
array [169, 172, 173] and changes in the array affect H3K4me3
enrichment, hotspot recombination, and crossover patterns
[173]. Furthermore, sequence variation in PRDM9 may
underlie the intra- and interspecies differences observed in
recombination hotspot distribution [169, 174]. While the
exact mechanism linking hotspot specification with targeting
of the DSB machinery is unclear, it has been proposed that
PRDM9 may recruit Spo11, itself or via a partner protein,
or may promote chromatin remodelling permissive for Spo11
binding [173].
Negative feedback systems acting both in cis and in trans
also exert an inhibitory effect from one DSB on further break
formation, thus limiting DSB frequency [8]. In addition,
DSB formation occurs at unsynapsed chromosome segments,
implicating interhomolog interactions in the control of
DSB site and numbers [8, 175]. Recombination exhibits an
interhomolog bias as opposed to occurring between sister
chromatids [176] and it has recently been shown that total
DSB number itself is a determinant of DSB repair pathway
selection and development of biased recombination [177].
DSB formation is also subject to spatial regulation via
control of chromosome ultrastructure. During the leptotene
stage of prophase I, DSB formation occurs alongside the
development of the axial element, a proteinaceous axis com-
prising various proteins including cohesin [145]. The sister
chromatids form linear arrays of chromatin loops which are
connected at their bases by the axial element, which is the
precursor of the lateral element of the synaptonemal complex
at pachytene [145]. Sites of DSB formation are found to map
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to loop sequences which are “tethered” to the axis during
recombination in “tethered loop-axis complexes” [178]. ChIP-
chip studies in S. cerevisiaehave shown that Rec114,Mer2, and
Mei4 stably associate with chromosome axis association sites
between loops, in a manner dependent on components of the
axial element [179].Meiotic cohesinwas found to controlDSB
formation and axial element protein and RMM recruitment
at a subset of chromatin domains, while cohesin-independent
DSB formation was observed in other domains [179]. Such
differences in DSBmachinery deposition between chromatin
domains may contribute to the establishment of different
recombination proficiencies, potentially providing a form of
spatial regulation of DSB induction [179]. Furthermore, this
interaction of RMM with axis association sites is dependent
on Mer2 phosphorylation by Cdc28 which likely affords
additional temporal coordination of DSB formation with the
end of premeiotic replication [179].
3. Manipulation of DNA Topology: DSBs as
Genomic Sculptors
3.1. Physiological DSBs in the Relief of Topological Stress. To
access the information stored in compacted nuclear DNA
in such processes as transcription, replication, and repair
requires the repeated tangling and untangling of the DNA
double helix. Such molecular contortions introduce topolog-
ical entanglements into the duplex which if left unchecked
could compromise genomic stability [180, 181]. Relief of
such topological strain is achieved by a family of essential
enzymes, the type I and type II topoisomerases. The former
generate transient single-strand breaks (SSBs) while the latter
family hydrolyse ATP to cut the DNA double helix and
generate a transient DSB.The type II enzyme then passes one
DNA duplex through the gap, and the gap is subsequently
resealed [182]. Type II topoisomerase (Top II) activity in
mammals is mediated by two isoenzymes, Top IIa and Top
IIb, which exhibit considerable homology except in their
less conserved C-termini [183, 184] and display different
subcellular distributions during the cell cycle [185, 186].
Studies on Top IIa/b chimeric “tail swap” proteins and C-
terminal truncations have shown that the C-terminal regions
contribute to isoform-specific functionality and may mod-
ulate decatenation activity [187, 188]. Immunohistochemical
studies of Top II isoform expression patterns in normal and
neoplastic human tissues show that Top IIa expression is
largely restricted to normal proliferative tissue and is highly
expressed in certain tumour types. In contrast, Top IIb is
widely expressed across both proliferative and quiescent cell
populations, although at a higher level in normal proliferative
tissue and tumours [189, 190].
While, in general, a Top II-induced DSB is resolved
in the enzyme’s catalytic cycle, it does possess a capacity
for formation of abortive breaks [19] and can form longer-
lived complexes in certain functions [12, 191] and both
inappropriately low or excessive formation of DSB interme-
diates can compromise cellular viability, thus necessitating
commensurate regulation [18]. The critical involvement of
DNA topoisomerases in various essential cellular processes
has led to the development of topoisomerase poisons for use
as antibacterial [192, 193] or anticancer therapeutics [194, 195].
While catalytic inhibitors block enzymatic activity without
trapping of the covalently linked DNA-enzyme intermediate
cleavage complex, the majority of clinically used Top II-
targeting drugs act as Top II poisons, accumulating com-
plexes by either blocking religation or increasing complex
formation. The resultant DSBs drive mitotic arrest and
apoptotic cell death, illustrating the toxicity of uncontrolled
DSB physiology [196]. The tight spatiotemporal regulation of
Top II-mediated DSB formation enables the measured usage
of these potentially deleteriousDNAbreaks as a physiological
tool for the relief of topological stress.
3.1.1. Type II Topoisomerase DSB Handling. Supercoiling,
entanglement, and knotting are frequent topological obsta-
cles encountered in DNA physiology. Type II DNA topoi-
somerases, through DSB induction and repair, act to re-
solve such obstacles using a repertoire of supercoil in-
troduction/relaxation, catenation/decatenation, and knot-
ting/unknotting processes [197, 198]. Eukaryotic Top II
enzymes are homodimeric proteins with symmetrically
paired domains, whereof each interface serves as a “gate” to
control the passage of DNA strands [180]. While catalytic
efficiency is a function of the structural interplay between
the DNA substrate and the type II topoisomerase isoenzyme,
the general mechanism is conserved across the enzyme
family. The overall cycle acts to relax DNA, involving DSB
induction, strand passage, and DSB repair and proceeds via
a phosphotyrosine-linked DNA-enzyme intermediate [199].
The aforementioned DSB-dependent relief of DNA topolog-
ical tension is of particular importance in the processes of
DNA replication, transcription, and compaction into higher-
order structures.
3.2. Physiological DSBs in DNA Replication. Replication fork
arrest, such as due to impassable DNA damage, can give rise
to DSBs [200, 201] which are highly mutagenic and cytotoxic
and elicit a potent DDR comprising HR-mediated repair, cell
cycle arrest, and possibly apoptosis, to ensure the faithful
inheritance of genetic information [202–204]. Indeed, drugs
which promoteDSB formation or target DSB repair represent
an important category of chemotherapeutics for cancer [205,
206]. In spite of all this, Top II-induced DSBs play an integral
role in replication, illustrating how the careful regulation of
a potentially destructive lesion can be exploited for cellular
physiology.
Top II enzymes are essential in the elongation of repli-
cating DNA chains and during segregation of newly repli-
cated chromosomes. During semiconservative replication,
the replisomal machinery at the advancing replication fork
forces the intertwined DNA strands ahead of it to become
overwound or positively supercoiled. These positive super-
coils are redistributed behind the fork by the rotation of
the replicative machinery around the helical axis of the
parental duplex. This causes intertwinement of the newly
replicated DNA double helices, forming precatenanes [197].
Studies in yeast reveal a necessity of either Top I or Top
II in elongation, acting as replication “swivels” to relax
positive supercoiling and resolve precatenanes, respectively
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[9, 207–209]. As replication nears completion, the unrepli-
cated double-stranded DNA (dsDNA) segment in between
the converging forks becomes too short for the action of a
type I topoisomerase and replication must first be completed
resulting in intertwinement of the replicated duplexes into
catenated dimers [208, 210]. These intertwines are decate-
nated by the action of Top II to allow for chromosome
separation inmitosis [211, 212]. In yeast, which only possesses
a single type II topoisomerase, loss of the enzyme results
in chromosome nondisjunction, accumulation of catenated
dimers, and inviability at mitosis [211, 213, 214]. In contrast, it
has been shown in human cells that Top IIa but not Top IIb is
essential for chromosome segregation [215].
3.3. Physiological DSBs in Transcription. Transcription of
nascent mRNA presents topological obstacles akin to those
seen during replication [216]. Transcription elongation is
accompanied by changes in the local supercoiled state of
DNA, forming positive supercoils ahead and negative super-
coils behind the transcriptional machinery [197, 198, 216,
217]. While loss of Top I or Top II alone in yeast generally
does not compromise transcription, top1 top2 temperature-
sensitive double mutants exhibit significant inhibition of
rRNA synthesis and, to a lesser extent, mRNA synthesis
at nonpermissive temperatures [207]. In addition, double
mutants accumulate negative supercoils in extrachromoso-
mal plasmids which appear to promote transcription initi-
ation of ribosomal minigenes on such plasmids [218, 219].
More recent studies of yeast rRNA synthesis suggest distinct
roles of Top II and Top I, acting, respectively, to relieve
positive supercoiling ahead of and negative supercoiling
behind the advancing polymerase [11]. Pharmacological inhi-
bition of Top II in human cells is found to decrease Pol
I transcription and Top IIa depletion both impairs Pol I
preinitiation complex (PIC) formation and produces a loss
of DSBs at these sites. It has thus been proposed that Top IIa-
induced DSBs are involved in topological changes at rDNA
promoters to facilitate PIC formation [220].
As aforementioned, top2 yeast exhibits normal levels of
transcription; however it has been shown in budding yeast
that loss of Top2 produces a specific reduction in Pol II-
dependent transcription of genes longer than around 3 kb,
attributed to defective elongation due to Pol II stalling [221].
More recently, Top II-induced DSBs have been proposed
to act in a mechanism involving the transcription factor
TRIM28 andDNAdamage signalling to promote Pol II pause
release and transcription elongation [222].
3.3.1. Activity-Induced DSBs in Transcription Regulation.
Transcription has long been known to stimulate HR in a
locus-specificmanner [223–225] and it is emerging that phys-
iological DSBs may be involved in regulated transcription
[191, 222]. Furthermore, it has recently been found that DSBs
induced at transcriptionally active sites in human cells prefer-
entially promote HR over NHEJ and this repair is dependent
on the transcription elongation-associated epigenetic marker
H3K36me3 [226]. It is thus becoming increasingly clear
that transcription and HR-dependent DSB repair may be
reciprocally regulated. Of particular interest is the emerging
role of so-called “activity-induced DSBs” in transcriptional
control, adding additional complexity to the integration of
environmental stimuli and cell state to the modulation of
transcriptional programmes. Indeed, Top IIb has previously
been shown to be required for 17𝛽-estradiol-dependent
transactivation, via the regulated formation of site-specific
longer-lived DSBs in target gene promoters [191]. Top IIb-
mediated DSB formation in a target promoter has also been
shown to be required for glucocorticoid receptor-dependent
transactivation [227]. More recently, the spotlight has shifted
to the broadening role of activity-induced DSBs in neuronal
physiology and neuropathology.
3.3.2. Role of Activity-Induced DSBs in Neuronal Function.
Neuronal early response genes or “immediate early genes”
(nIEGs) are a subset of activity-regulated genes induced with
shortest latency following neuronal stimulation and typi-
cally encode transcription factors involved in transcriptional
modulation for synaptic plasticity [228, 229]. Treatment of
neuronal cells with etoposide, a Top II inhibitor which
induces Top II-mediated DSBs [230], has been found to pro-
mote upregulation of a subset of nIEGs including Fos, FosB,
and Npas4 [12]. This increase was not observed with other
DSB-inducing agents including neocarzinostatin, bleomycin,
and olaparib, suggesting a Top II-mediated mechanism [12].
Furthermore, etoposide-induced upregulation of Fos and
Npas4 is not affected by inhibition ofDSB signalling following
ATM blockade, which also suggests that nIEG induction is
independent of the effects of a generic DDR to nonspecific
DSBs [12]. Similar to etoposide treatment, CRISPR-Cas9-
induced DSBs targeted to the Fos and Npas4 promoters also
produced upregulation thereof in the absence of neuronal
activity. Together these indicate a role of DSBs acting within
target gene promoters in the regulation of nIEG transcription
[12].
Furthermore, electrical or pharmacological stimulation
of cultured primary neurons revealed upregulation of Fos
and Npas4 mRNA accompanied by elevated 𝛾H2AX levels
[12], a known biomarker of DSB formation [231], suggesting
the possible involvement of “activity-induced DSBs” in nIEG
expression. Genome-wide ChIP-seq of 𝛾H2AX following
stimulation with NMDA (N-methyl-D-aspartate) demon-
strated preferential clustering of yH2AX elevations at actively
transcribed genes and downstream sequences. Differential
peak calling on NMDA-treated samples showed that yH2AX
enrichment was confined to only 21 loci including the nIEGs
Fos, FosB, Npas4, Egr1, Nr4a1, and Nr4a3 among other
transcription factors and noncoding RNAs, pointing to the
specific localisation of DSB induction following neuronal
stimulation [12]. Interestingly, 𝛾H2AX was also observed to
increase following pharmacological or electrical stimulation
of mouse acute hippocampal slices as well as in hippocampal
lysates from mice exposed to a fear-conditioning paradigm
[12]. This corroborates recent evidence supporting DSB
induction in mouse neurons in response to environmental
stimuli in the form of spatial exploration [232]. These DSBs
were found to predominate in the dentate gyrus suggest-
ing a physiological role in spatial learning and memory
[232]. Overall, these results suggest that neuronal activity
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specifically induces targeted DSBs involved in transcriptional
regulation of nIEGs. Interestingly, studies of repair kinetics
of DSBs generated in the Fos promoter following NMDA
treatment demonstrated long-lived breaks, being repaired
within 2 hours of stimulation. However, the significance of
this extended lifespan is as yet unclear [12].
Other experiments showed that short hairpin RNA-
mediated knockdown of Top2b in cultured primary neurons
reduces yH2AX enrichment at nIEG exons following NMDA
stimulation, pointing towards a role of Top IIb in activity-
induced DSB formation at nIEGs [12]. In ChIP-seq experi-
ments, genome-wide binding of Top IIb was found to almost
quintuple following NMDA treatment and it was observed
that Topo IIb enrichment clustered alongside yH2AX sig-
nals in both unstimulated and NMDA-treated cells [12]. In
addition, yH2AX-enrichment following NMDA stimulation
and etoposide treatment were strongly correlated, lending
further support to a model of Top IIb-generated activity-
inducedDSBs [12]. Linking Top IIb-mediatedDSB formation
with activity-dependent nIEG transcription, it was found
that Top2b knockdown in cultured primary neurons inhibits
induction of nIEGs following NMDA stimulation but could
be rescued by Cas9-generated DSBs targeted to the nIEG
promoter [12].
While the mechanism whereby Top IIb-mediated DSBs
could induce nIEG transcription is as yet unclear, one
model proposed involves a functional interaction with the
architectural protein CTCF [12]. CTCF organises genomic
superstructure, defining chromatin architecture to control
long-range interactions between different genomic loci.
Major effects of CTCF action include the establishment
of chromatin domains and blockade of promoter-enhancer
interactions [233]. Searches for motif enrichment at Top
IIb binding sites have revealed greatest clustering of CTCF
under both basal conditions and NMDA treatment [12]
and Top IIb itself is found to concentrate within CTCF
motifs. Furthermore, Top IIb is found to coimmunopre-
cipitate with CTCF both under basal conditions and to a
greater extent with NMDA stimulation. Genome-wide CTCF
binding distribution also corresponds well with yH2AX
signals at NMDA-stimulated activity-induced DSBs and fol-
lowing etoposide [12]. Combining these results Madabhushi
et al. [12] propose a model whereby neuronal activity drives
Top IIb-induced DSB formation which relieves CTCF-based
topological impediments to nIEG transcription. While a
recent proteomic analysis of the Top IIb proximal protein
interaction network revealed interaction of Top IIb with
CTCF at topologically associating domain (TAD) boundaries
[234], the precisemechanismwhereby activity-inducedDSBs
may overcome CTCF-generated obstacles is unknown. It was
recently postulated that activity-induced DSBs in nIEGs lead
to genomic rearrangements involving transposable elements
producing a distinct form of somatic mosaicism in neu-
rons, with implications on plasticity, network formation, and
potential interplay with age-related epigenetic changes and
disease [235].
Additional mechanistic complexity derives from the need
for concerted repair of activity-induced DSBs. Top IIb
exhibits preferential binding and cleavage at the promoters
of target nIEGs, cooccupying the site with the transcriptional
activator ELK1 and histone deacetylase HDAC2, the latter
repressing nIEG expression [236]. Also found enriched at
these sites is the tyrosyl-DNA phosphodiesterase TDP2
which acts via the NHEJ pathway to repair abortive Top IIb-
induced DSBs [19, 237, 238], suggesting coordinated resolu-
tion of such physiological breaks [12]. Furthermore, TDP2-
deficiency in human cells produces hypersensitivity to Top II-
induced DSBs and reduces Top II-dependent transcription,
illustrating the importance of regulated break repair in DSB
physiology [19].
3.3.3. Dysregulation of Physiological DSBs in Neuropathology.
Defective DSB repair and/or loss of DSB repair components
is a feature of various neuropathologies and age-associated
neurodegenerative disorders, including ataxia-telangiectasia
(ATM), ataxia-telangiectasia-like disorder (MRE11), Nijme-
gen breakage syndrome (NBS1), and Alzheimer’s disease
[239–245]. In addition, Ercc1Δ/− mice, which have compro-
mised nucleotide excision repair, interstrand crosslink repair,
and DSB repair pathways, display age-associated neurode-
generation and progressive loss of motor function [246, 247].
Increased incidence of DNA strand breakage has been
identified in the brains of Alzheimer’s disease (AD) patients
[248, 249], andADmousemodels exhibit an elevated baseline
frequency of neuronal DSBs [232]. Furthermore, amyloid-𝛽
(A𝛽), aggregates of which are widely recognised as a key fac-
tor in AD pathogenesis, is found to increase DSB formation
in primary neuronal cultures via dysregulation of synaptic
transmission [232, 250]. Expression of BRCA1, an important
HR DSB repair factor [251, 252], is found to be reduced
in AD brains and exhibits neuronal activity-dependent reg-
ulation as well as downregulation by A𝛽 oligomers [253].
Moreover, short hairpin RNA knockdown of BRCA1 in
wild-type mice impairs repair of activity-induced DSBs
[253].
There is growing evidence suggesting that aberrant Top
II activity may play a role in the aetiology of neurodevelop-
mental defects. Recent work involving clinical whole-exome
sequencing identified a novel TOP2B mutation associated
with intellectual disability, autistic traits, microcephaly, and
developmental retardation [254] and homozygous mutations
in TDP2 have been linked with cases of intellectual disability,
epilepsy, and ataxia [19]. Top IIb has been shown to be
important in neuronal differentiation and survival and is
upregulated during the transition from mouse embryonic
stem cells to postmitotic neurons with reciprocal downregu-
lation of Top IIa. Furthermore, loss of Top IIb in mice results
in premature degeneration and apoptosis of neurons at later
stages of differentiation concomitant with transcriptional
deregulation of genes involved in neurogenesis and cell
division [13, 14]. Pharmacological inhibition of Top I in
mouse cortical neurons results in preferential downregula-
tion of long genes, many of which are associated with autism
spectrum disorder. As Top IIa/b inhibition by ICRF-193
produces a similar length-dependent transcriptional reduc-
tion, it is possible that Top II is also responsible for the
regulation of certain autism-associated candidate genes [255].
Furthermore, it has been proposed that environmental and
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dietary sources of topoisomerase poisons and inhibitors in
early neurodevelopment could be a potential cause of autism
and there have been calls to factor this into food safety and
risk assessments [256, 257].
Together, these findings point towards the importance of
DSB repair regulation in neuronal physiology and activity-
induced DSB handling, but further studies will be required
to elucidate more specific roles of activity-induced DSBs in
neuropathology.
3.4. Physiological DSBs in Chromatin Architecture. Top II is
a highly abundant chromatin protein, constituting 1-2% of
total chromosomal protein content in mitosis [258]. Studies
of isolated chromosomes reveal association of one Top II
molecule per 23,000 base pairs of DNA, largely at and
around loop bases, suggesting a structural role in higher-
order DNA architecture [258, 259]. Indeed, Top II binding
and DSB formation sites have been identified in matrix-
attachment regions, cis-elements which are involved in long-
range chromatin organisation [260, 261]. However, photo-
bleaching experiments have revealed both Top II isoforms to
be highly mobile in the chromosomal scaffold, arguing for a
more complex dynamic interaction with chromatin structure
[262].
DNA topology and chromatin structural changes are
known to be intricately related [263]. Early work with
temperature-sensitive top2 yeast [212] and complementa-
tion experiments with Top II-immunodepleted Xenopus egg
extracts [264] revealed Top II to be important in chromo-
some condensation and segregation in mitosis, presaging
the discovery of a more active role of the enzyme in chro-
matin remodelling. Indeed, Top II has been identified as
a component of the Drosophila ATP-dependent chromatin
remodelling complex CHRAC (chromatin-accessibility com-
plex) [265], and mammalian BAF chromatin remodelling
complexes are found to promote Top IIa activity [266].
Furthermore, Top II-mediated DNA supercoil relaxation is
stimulated by the Drosophila protein Barren [267], which
is involved in chromosome condensation and disjunction
[268]. ChIP experiments in S. pombe demonstrate an inter-
genic localisation of both Top I and Top II which strongly
correlates with distributions of the chromodomain ATPase
Hrp1 and the histone chaperoneNap1, both involved in nucle-
osome disassembly [269–271]. Top II-dependent chromatin
remodelling is also important in apoptotic chromosome con-
densation, and caspase-activated DNase (CAD) association
is found to promote Top IIa activity [272]. While the exact
mechanistic role of DSB handling in chromatin packing is
unclear, AFM and fluorescence imaging have revealed an H1-
dependent ATP-independent mechanism of Top II-mediated
chromatin compaction involving clamping of DNA strands
[273]. Thus, it appears that Top II DSB handling is important
in highly diverse manipulations of chromatin packing and
further studies are needed to elucidate the precise regulation
thereof.
3.5. Mitochondrial DNA Maintenance and Ageing. Mito-
chondrial DNA (mtDNA) in humans is typically a closed
circle of dsDNA [274]. As in genomic DNA, replication and
transcription processes exert topological stresses on mtDNA
molecules which are relieved by native topoisomerases [197,
275]. Mammalian mitochondria contain 3 topoisomerases
encoded in the nucleus: Top1mt (TOP1MT) and Top III𝛼
(TOP3A) of the type I family and Top IIb (TOP2B) from
the type II family of enzymes [275]. Although mitochon-
drial Top IIb is C-terminally truncated compared to its
nuclear counterpart, it still retains basic type II topoisomerase
DSB turnover activity, albeit with reduced processivity, and
exhibits a similar pharmacological profile [276]. Top1mt
deletion inmice results in elevatedmtDNA transcription and
induction of a stress response accompanied by considerable
upregulation of Top IIb, suggesting a potential compensatory
role of the type II enzyme [277]. However, both TOP2B−/−
MEFs and TOP1MT−/−TOP2B−/− display wild-type levels of
transcription and only the double-knockout elicits a stress
response, suggesting nonoverlapping functions of the two
molecules [277]. This picture is further complicated by the
recent discovery of active full-length Top IIa and Top IIb in
both murine and human mitochondria, which, although as
yet uncharacterised, are likely involved in classical functions
in replication and transcription like their nuclear counter-
parts [278].
Top IIIa is a type IA topoisomerase which is found in both
the nucleus and mitochondria and has been shown to play a
crucial role in the maintenance of mtDNA genomic integrity
in Drosophila. Indeed, loss of mitochondrial import of Top
IIIa in Drosophila is associated with a reduction in mtDNA
copy number, mitochondrial dysfunction, impaired fertility,
and accelerated ageing [279, 280]. The interplay between
these type I and II topoisomerases in the maintenance of
mtDNA and the precise roles of DSB handling therein will
require further investigation.
A recently proposed but unexplored theory suggests
that mitochondrial Top II may be involved in ageing [275].
With age, mtDNA undergoes attrition through entanglement
and/or recombination such that mtDNA deletion is increas-
ingly observed over time. These deletion events are found
to contribute to dysfunction of the respiratory chain [281]
and other tissue impairments associated with ageing [282–
287]. One hypothesis postulates that age-related attrition
occurs as a result of mitochondrial “poisoning” by exoge-
nous agents, resulting in dysregulation of topoisomerase II-
mediated DSB handling [275]. Many such “poisons” disrupt
the ligation step of Top II, resulting in accumulation of DSB-
enzyme intermediates [275]. Mammalian mitochondrial Top
IIb has been found to be inhibited by the anticancer drugs
amsacrine and teniposide [288] and it is possible that
various known nuclear Top II poisons, ranging from the
fungal toxin alternariol [289] and chemotherapeutics [290]
to dietary components such as bioflavonoids from fruit and
vegetables [291], may also inhibit the truncated or full-
length type II topoisomerases inmitochondria. Furthermore,
base oxidations, abasic sites, and other exogenously induced
base modifications can act, via an unknown mechanism,
to abnormally enhance Top II DSB formation [292] and
promote accumulation of DNA-enzyme intermediates at sites
of damage [293]. Combined with the finding that DSBs in
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the mitochondrial genome can induce considerable mtDNA
deletion [294], Sobek and Boege speculate that exposure
to mitochondrial topoisomerase “poisons” over time with
age could lead to potential DSB-dependent mtDNA attrition
[275]. While it is likely that mitochondrial Top II performs
similar DSB-related functions to its nuclear counterpart,
further studies will be needed to elucidate the precise nature
of its role in mitochondria and its contribution if any to the
ageing process.
Further insight into the role of Top II-induced DSBs in
mitochondria may be drawn from parallels in Kinetoplastids,
a group of flagellated protozoa which includes the parasitic
Trypanosoma and Leishmania species, which possess a char-
acteristic dense granule of DNA called a kinetoplast within
their single mitochondrion. The kinetoplast consists of an
enormous network of catenated circular mtDNA (kDNA)
comprising short minicircles and much larger maxicircles
and thus represents a considerable topological challenge
in replication and segregation [295]. The mitochondrion
contains a type II topoisomerase which localises to the
kDNA [296, 297] and has been shown to be important for
the maintenance of structural integrity in the kinetoplast
[298], mending of holes in the kDNA following individual
minicircle release for replication [299], segregation of daugh-
ter minicircles [300], and their reattachment to the kDNA
network [301].
4. Concluding Remarks and Future Prospects
DSB physiology is thus, at its very core, a molecular surgery,
reliant on both calculated incisions and timely suturing
thereof, all the while, under the intense scrutiny of numerous
regulatory mechanisms. While the basic biochemical mech-
anisms of the processes discussed above are well established,
their multilateral spatiotemporal regulation remains a field of
active research.
The roles of recombination defects in human disease
and tumorigenesis are being increasingly appreciated and
further studies will be needed to examine the nature of the
dysregulation of DSB physiology in pathogenesis. New work
may reveal novel pharmacological targets for human disease
such as the possibility of targeting DSB signalling and repair
proteins in neurodegenerative conditions such as Alzheimer’s
disease, to lessen aberrant DSB formation.
Novel tissue-specific roles of topoisomerases in neuro-
physiology are only just being uncovered with future studies
required to elucidate the function of DSBs therein to under-
stand mechanisms of learning, memory, and cognition. In
addition, future work is necessary to characterise the nature
of mitochondrial DSB physiology and the as yet unexplored
implications on mitochondrial metabolism, disease, and
ageing.
Furthermore, both topoisomerases and cancer DSB
repair deficiencies are important areas of investigation in the
development of anticancer therapeutics, and an understand-
ing of the physiological roles of these targets in multiple dis-
parate processes will inform the design of specific inhibitors
with fewer off-target effects.
This account illustrates the breadth of DSB physiology
across cellular biology and adds a new dimension of com-
plexity to the regulation of genomic transactions on a basic
biochemical level. The emerging role of DSB-dependent
changes in topology, not only in replication and basal
transcription, but also in activity-induced transcriptional
changes, and potential roles in the chromatin landscape and
mitochondria paint a picture of a far more active role of DSBs
in fundamental DNA metabolism than previously thought.
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